FRE Stock Analysis: Fresenius SE & Co. KGaA | XETRA
Medical Care Facilities | XETRA, Germany | Market Cap: 25.388m EUR | 12M Return: -3.7% | DE000FRE5EN2 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 41.0M
EPS Trend: 97.3%
Qual. Beats: 0
Rev. Trend: -68.2%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Fresenius SE & Co. KGaA is a German healthcare company that operates globally across North America, Europe, Asia-Pacific, Latin America, and Africa, serving chronically and critically ill patients. Its business spans two main segments: Fresenius Kabi, which manufactures biopharmaceuticals, clinical nutrition products, IV generic drugs, IV fluids, biosimilars, and medical devices such as infusion pumps and apheresis machines; and Fresenius Helios, which runs hospitals, medical care centers, outpatient clinics, and prevention and occupational health centers, alongside medical diagnostics services.
The company is unusual within the Health Care Facilities sub-industry because it combines a pharmaceutical and medical-products manufacturer (Kabi) with a large hospital operator (Helios), exposing it to both drug/device demand cycles and hospital service volumes. Fresenius has a strategic collaboration with SAP SE and Avelios Medical GmbH to co-develop a cloud-native, AI-integrated hospital information system aimed at digitizing clinical and administrative workflows.
Founded in 1912, the company is headquartered in Bad Homburg vor der Höhe, Germany, and adopted its current legal form as a partnership limited by shares (KGaA) in January 2011. It is listed on the XETRA exchange under the ticker FRE and is classified as a large-cap stock.
- Kabi biosimilar and IV drug pricing pressures margins
- Helios hospital reimbursement cuts in Germany weigh on earnings
- High debt load limits capital allocation flexibility for buybacks
| Net Income: 1.52b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.46 > 1.0 |
| NWC/Revenue: 10.87% < 20% (prev 11.63%; Δ -0.76% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.96b > Net Income 1.52b |
| Net Debt (11.5b) to EBITDA (3.64b): 3.17 < 3 |
| Current Ratio: 1.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (563.2m) vs 12m ago 0.0% < -2% |
| Gross Margin: 25.25% > 18% (prev 25.40%; Δ -0.16% > 0.5%) |
| Asset Turnover: 56.29% > 50% (prev 53.79%; Δ 2.49% > 0%) |
| Interest Coverage Ratio: 8.28 > 6 (EBIT TTM 2.52b / Interest Expense TTM 304.0m) |
| A: 0.06 (Total Current Assets 11.6b - Total Current Liabilities 9.07b) / Total Assets 41.8b |
| B: 0.36 (Retained Earnings 15.0b / Total Assets 41.8b) |
| C: 0.06 (EBIT TTM 2.52b / Avg Total Assets 41.6b) |
| D: 0.92 (Book Value of Equity 19.7b / Total Liabilities 21.4b) |
| Altman-Z'' = 2.93 = A |
| DSRI: 1.13 (Receivables 6.22b/5.21b, Revenue 23.4b/22.2b) |
| GMI: 1.01 (GM 25.40% / 25.25%) |
| AQI: 0.97 (AQ_t 0.49 / AQ_t-1 0.50) |
| SGI: 1.05 (Revenue 23.4b / 22.2b) |
| TATA: -0.03 (NI 1.52b - CFO 2.96b) / TA 41.8b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of October 28, 2026, the stock is trading at EUR 46.26 with a total of 493,209 shares traded. Over the past week, the price has changed by +2.79%, over one month by -0.45%, over three months by +4.53% and over the past year by -3.74%.
Current recommended Stop Loss: 44.40 (which is 4% or 1.9 ATR below the current price).
Fresenius SE & Co. KGaA has no consensus analysts rating.
P/E Trailing = 16.6986
P/E Forward = 12.7551
P/S = 1.1239
P/B = 1.3283
P/EG = 0.8234
Revenue TTM = 23.4b EUR
EBIT TTM = 2.52b EUR
EBITDA TTM = 3.64b EUR
Long Term Debt = 8.33b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.86b EUR (from shortTermDebt, last quarter)
Debt = 12.8b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.40b
Net Debt = 11.5b EUR (calculated: Debt 12.8b - CCE 1.28b)
Enterprise Value = 36.9b EUR (25.4b + Debt 12.8b - CCE 1.28b)
Interest Coverage Ratio = 8.28 (Ebit TTM 2.52b / Interest Expense TTM 304.0m)
EV/FCF = 25.54x (Enterprise Value 36.9b / FCF TTM 1.45b)
FCF Yield = 3.92% (FCF TTM 1.45b / Enterprise Value 36.9b)
FCF Margin = 6.18% (FCF TTM 1.45b / Revenue TTM 23.4b)
Net Margin = 6.50% (Net Income TTM 1.52b / Revenue TTM 23.4b)
Gross Margin = 25.25% ((Revenue TTM 23.4b - Cost of Revenue TTM 17.5b) / Revenue TTM)
Gross Margin QoQ = 26.07% (prev 26.38%)
Tobins Q-Ratio = 0.88 (Enterprise Value 36.9b / Total Assets 41.8b)
Interest Expense / Debt = 2.37% (Interest Expense 304.0m / Debt 12.8b)
Taxrate = 25.66% (564.0m / 2.20b)
NOPAT = 1.87b (EBIT 2.52b * (1 - 25.66%))
Current Ratio = 1.28 (Total Current Assets 11.6b / Total Current Liabilities 9.07b)
Debt / Equity = 0.65 (Debt 12.8b / totalStockholderEquity, last quarter 19.7b)
Debt / EBITDA = 3.17 (Net Debt 11.5b / EBITDA 3.64b)
Debt / FCF = 7.98 (Net Debt 11.5b / FCF TTM 1.45b)
Total Stockholder Equity = 19.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.66% (Net Income 1.52b / Total Assets 41.8b)
RoE = 7.89% (Net Income TTM 1.52b / Total Stockholder Equity 19.3b)
RoCE = 9.11% (EBIT 2.52b / Capital Employed (Equity 19.3b + L.T.Debt 8.33b))
RoIC = 5.59% (NOPAT 1.87b / Invested Capital 33.5b)
WACC = 4.63% (E(25.4b)/V(38.2b) * Re(6.07%) + D(12.8b)/V(38.2b) * Rd(2.37%) * (1-Tc(0.26)))
Discount Rate = 6.07% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -40.89 | Cagr: 0.0%
[DCF] Terminal Value 77.97% ; FCFF base≈1.36b ; Y1≈1.56b ; Y5≈2.30b
[DCF] Fair Price = 40.93 (EV 34.6b - Net Debt 11.5b = Equity 23.1b / Shares 563.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.26 | EPS CAGR: 16.99% | SUE: -0.59 | # QB: 0
Revenue Correlation: -68.18 | Revenue CAGR: -11.93% | SUE: 0.52 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.81 | Chg30d=-0.02% | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=3.71 | Chg30d=-0.18% | Revisions=+38% | GrowthEPS=+4.8% | GrowthRev=+3.8%
EPS next Year (2027-12-31): EPS=3.94 | Chg30d=-0.38% | Revisions=+12% | GrowthEPS=+6.3% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: +21% (up=7, down=4)